Cell and Gene Therapy Biomanufacturing Market Forecast 2031

Market Research Report

A quick peek into the report

1.1   Market Outlook
1.1.1   Product Definition
1.1.2   Inclusion and Exclusion Criteria
1.1.3   Key Findings
1.1.4   Assumptions and Limitations
1.1.5   Market Growth Scenarios
1.1.5.1.1   Realistic Growth Scenario
1.1.5.1.2   Optimistic Growth Scenario
1.1.5.1.3   Pessimistic Growth Scenario
1.2   Industry Outlook
1.2.1   Market Overview and Ecosystem
1.2.2   Key Trends
1.2.2.1   Biomanufacturing 4.0
1.2.2.2   Growing Single-Use Technology Market Penetration
1.2.2.3   Shift from Open Processing to Closed Processing for Cell and Gene Therapy Biomanufacturing
1.2.2.4   Leveraging Various Key Strategies to Diversify the Product Portfolio
1.2.3   Opportunity Assessment
1.2.4   Regulatory Framework
1.2.5   Product Benchmarking
1.2.5.1   Product Benchmarking (by Product Type)
1.2.5.2   Comparative Analysis (by Equipment)
1.2.6   Patent Analysis
1.2.6.1   Patent Analysis (by Year)
1.2.6.2   Patent Analysis (by Country)
1.2.6.3   Awaited Technologies
1.2.7   Business Model Analysis
1.2.8   Pipeline Products
1.2.9   Technology Adoption Matrix
1.2.10   Funding Scenario
1.2.11   Key Success Factors
1.3   Business Dynamics
1.3.1   Business Drivers
1.3.1.1   Increasing Number of Approved Therapies and Growing Infrastructure Requirements Creating an Upsurge Demand for Cell and Gene Therapy Biomanufacturing Products
1.3.1.2   Expansion in Target Indications for Cell and Gene Therapies Creating a Demand for Large-Scale Biomanufacturing
1.3.1.3   Entry of New Market Participants in Cell and Gene Therapies Driving the Demand for Biomanufacturing Facilities and Equipment
1.3.1.4   Increasing Investments and Fundings in Cell and Gene Therapy Fuelling the Growth of Cell and Gene Therapy Biomanufacturing
1.3.1.5   Impact Analysis
1.3.2   Business Restraints
1.3.2.1   High Set-Up Cost of Biomanufacturing Facilities
1.3.2.2   Impact Analysis
1.3.3   Business Opportunities
1.3.3.1   Integration of Automation into the Cell and Gene Therapy Biomanufacturing Workflow
1.3.3.2   Robust Clinical Pipeline Creating a Demand for Biomanufacturing Infrastructure
1.4   Impact of COVID-19 on the Cell and Gene Therapy Biomanufacturing Market
1.4.1   Recommendations to Manufacturers
1.5   Impact of Russo-Ukrainian War on Cell and Gene Therapy Biomanufacturing Market

2.1   Overview
2.2   Opportunity Assessment
2.3   Consumables
2.3.1   Culture Supplements
2.3.1.1   Media
2.3.1.2   Serum
2.3.1.3   Macronutrients
2.3.2   Single-Use Liquids
2.3.3   Cell Culture Reagents
2.3.4   Cell Quantification Kits
2.4   Equipment
2.4.1   Bioreactors/Fermenters
2.4.1.1   Continuous Bioreactors
2.4.1.2   Single-Use Bioreactors
2.4.2   Mixing Systems
2.4.3   Cell Counters
2.4.4   Cell Sorters
2.4.5   Centrifuges
2.4.6   Incubators
2.4.7   Biosafety Cabinets
2.4.8   Freezers
2.4.9   PCR Systems
2.4.10   Transfection Systems
2.4.11   Storage Tanks
2.4.12   Others
2.5   Software Solutions

3.1   Overview
3.2   Opportunity Assessment
3.3   Upstream Processing
3.3.1   Formulation and Hydration
3.3.2   Cell Culture Processing
3.4   Harvesting
3.5   Downstream Processing
3.5.1   Separation and Filtration
3.5.2   Fill and Finish Operations

4.1   Overview
4.2   Opportunity Assessment
4.3   Commercial Stage Manufacturing
4.4   Research Stage Manufacturing

5.1   Overview
5.2   Opportunity Assessment
5.3   Life Sciences Companies
5.3.1   Equipment
5.3.2   Consumables
5.3.3   Software Solutions
5.4   Contract Research Organizations (CROs)
5.4.1   Equipment
5.4.2   Consumables
5.4.3   Software Solutions
5.5   Contract Manufacturing Organizations (CMOs)
5.5.1   Equipment
5.5.2   Consumables
5.5.3   Software Solutions
5.6   Cell Banks
5.6.1   Equipment
5.6.2   Consumables
5.6.3   Software Solutions

6.1   North America
6.1.1   Key Findings and Opportunity Assessment
6.1.2   Market Dynamics
6.1.2.1   Impact Analysis
6.1.3   Sizing and Forecast Analysis
6.1.3.1   North America Cell and Gene Therapy Biomanufacturing Market (by Product Type)
6.1.3.2   North America Cell and Gene Therapy Biomanufacturing Market (by End User)
6.1.3.3   North America Cell and Gene Therapy Biomanufacturing Market (by Country)
6.1.3.3.1   U.S.
6.1.3.3.1.1   U.S. Cell and Gene Therapy Biomanufacturing Market (by Product Type)
6.1.3.3.1.2   U.S. Cell and Gene Therapy Biomanufacturing Market (by End User)
6.1.3.3.2   Canada
6.1.3.3.2.1   Canada Cell and Gene Therapy Biomanufacturing Market (by Product Type)
6.1.3.3.2.2   Canada Cell and Gene Therapy Biomanufacturing Market (by End User)
6.2   Europe
6.2.1   Key Findings and Opportunity Assessment
6.2.2   Market Dynamics
6.2.2.1   Impact Analysis
6.2.3   Sizing and Forecast Analysis
6.2.3.1   Europe Cell and Gene Therapy Biomanufacturing Market (by Product Type)
6.2.3.2   Europe Cell and Gene Therapy Biomanufacturing Market (by End User)
6.2.3.3   Europe Cell and Gene Therapy Biomanufacturing Market (by Country)
6.2.3.3.1   Germany
6.2.3.3.1.1   Germany Cell and Gene Therapy Biomanufacturing Market (by Product Type)
6.2.3.3.1.2   Germany Cell and Gene Therapy Biomanufacturing Market (by End User)
6.2.3.3.2   Italy
6.2.3.3.2.1   Italy Cell and Gene Therapy Biomanufacturing Market (by Product Type)
6.2.3.3.2.2   Italy Cell and Gene Therapy Biomanufacturing Market (by End User)
6.2.3.3.3   U.K.
6.2.3.3.3.1   U.K. Cell and Gene Therapy Biomanufacturing Market (by Product Type)
6.2.3.3.3.2   U.K. Cell and Gene Therapy Biomanufacturing Market (by End User)
6.2.3.3.4   Spain
6.2.3.3.4.1   Spain Cell and Gene Therapy Biomanufacturing Market (by Product Type)
6.2.3.3.4.2   Spain Cell and Gene Therapy Biomanufacturing Market (by End User)
6.2.3.3.5   France
6.2.3.3.5.1   France Cell and Gene Therapy Biomanufacturing Market (by Product Type)
6.2.3.3.5.2   France Cell and Gene Therapy Biomanufacturing Market (by End User)
6.2.3.3.6   Rest-of-Europe
6.2.3.3.6.1   Rest-of-Europe Cell and Gene Therapy Biomanufacturing Market (by Product Type)
6.2.3.3.6.2   Rest-of-Europe Cell and Gene Therapy Biomanufacturing Market (by End User)
6.3   Asia-Pacific
6.3.1   Key Findings and Opportunity Assessment
6.3.2   Market Dynamics
6.3.2.1   Impact Analysis
6.3.3   Sizing and Forecast Analysis
6.3.3.1   Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type)
6.3.3.2   Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by End User)
6.3.3.3   Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Country)
6.3.3.3.1   China
6.3.3.3.1.1   China Cell and Gene Therapy Biomanufacturing Market (by Product Type)
6.3.3.3.1.2   China Cell and Gene Therapy Biomanufacturing Market (by End User)
6.3.3.3.2   Japan
6.3.3.3.2.1   Japan Cell and Gene Therapy Biomanufacturing Market (by Product Type)
6.3.3.3.2.2   Japan Cell and Gene Therapy Biomanufacturing Market (by End User)
6.3.3.3.3   India
6.3.3.3.3.1   India Cell and Gene Therapy Biomanufacturing Market (by Product Type)
6.3.3.3.3.2   India Cell and Gene Therapy Biomanufacturing Market (by End User)
6.3.3.3.4   South Korea
6.3.3.3.4.1   South Korea Cell and Gene Therapy Biomanufacturing Market (by Product Type)
6.3.3.3.4.2   South Korea Cell and Gene Therapy Biomanufacturing Market (by End User)
6.3.3.3.5   Australia/New Zealand
6.3.3.3.5.1   Australia/New Zealand Cell and Gene Therapy Biomanufacturing Market (by Product Type)
6.3.3.3.5.2   Australia/New Zealand Cell and Gene Therapy Biomanufacturing Market (by End User)
6.3.3.3.6   Rest-of-Asia-Pacific
6.3.3.3.6.1   Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type)
6.3.3.3.6.2   Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by End User)
6.4   Latin America
6.4.1   Key Findings and Opportunity Assessment
6.4.2   Market Dynamics
6.4.2.1   Impact Analysis
6.4.3   Sizing and Forecast Analysis
6.4.3.1   Latin America Cell and Gene Therapy Biomanufacturing Market (by Product Type)
6.4.3.2   Latin America Cell and Gene Therapy Biomanufacturing Market (by End User)
6.4.3.3   Latin America Cell and Gene Therapy Biomanufacturing Market (by Country)
6.4.3.3.1   Argentina
6.4.3.3.1.1   Argentina Cell and Gene Therapy Biomanufacturing Market (by Product Type)
6.4.3.3.1.2   Argentina Cell and Gene Therapy Biomanufacturing Market (by End User)
6.4.3.3.2   Brazil
6.4.3.3.2.1   Brazil Cell and Gene Therapy Biomanufacturing Market (by Product Type)
6.4.3.3.2.2   Brazil Cell and Gene Therapy Biomanufacturing Market (by End User)
6.4.3.3.3   Mexico
6.4.3.3.3.1   Mexico Cell and Gene Therapy Biomanufacturing Market (by Product Type)
6.4.3.3.3.2   Mexico Cell and Gene Therapy Biomanufacturing Market (by End User)
6.4.3.3.4   Rest-of-Latin America
6.4.3.3.4.1   Rest-of-Latin America Cell and Gene Therapy Biomanufacturing Market (by Product Type)
6.4.3.3.4.2   Rest-of-Latin America Cell and Gene Therapy Biomanufacturing Market (by End User)
6.5   Middle East and Africa
6.5.1   Key Findings and Opportunity Assessment
6.5.2   Market Dynamics
6.5.2.1   Impact Analysis
6.5.3   Sizing and Forecast Analysis
6.5.3.1   Middle East and Africa Cell and Gene Therapy Biomanufacturing Market (by Product Type)
6.5.3.2   Middle East and Africa Cell and Gene Therapy Biomanufacturing Market (by End User)
6.5.3.3   Middle East and Africa Cell and Gene Therapy Biomanufacturing Market (by Country)
6.5.3.3.1   Kingdom of Saudi Arabia
6.5.3.3.1.1   Kingdom of Saudi Arabia Cell and Gene Therapy Biomanufacturing Market (by Product Type)
6.5.3.3.1.2   Kingdom of Saudi Arabia Cell and Gene Therapy Biomanufacturing Market (by End User)
6.5.3.3.2   U.A.E.
6.5.3.3.2.1   U.A.E. Cell and Gene Therapy Biomanufacturing Market (by Product Type)
6.5.3.3.2.2   U.A.E. Cell and Gene Therapy Biomanufacturing Market (by End User)
6.5.3.3.3   Israel
6.5.3.3.3.1   Israel Cell and Gene Therapy Biomanufacturing Market (by Product Type)
6.5.3.3.3.2   Israel Cell and Gene Therapy Biomanufacturing Market (by End User)
6.5.3.3.4   Rest-of-Middle East and Africa
6.5.3.3.4.1   Rest-of-Middle East and Africa Cell and Gene Therapy Biomanufacturing Market (by Product Type)
6.5.3.3.4.2   Rest-of-Middle East and Africa Cell and Gene Therapy Biomanufacturing Market (by End User)

7.1   Competitive Benchmarking
7.1.1   Competitive Landscape
7.1.1.1   Segmental Growth Share Matrix
7.1.1.1.1   Growth Share Analysis (by Product Type)
7.1.1.1.2   Growth Share Analysis (by Application)
7.1.1.2   Competitive Index (Unmet Needs and Innovations)
7.1.1.3   Company Position Analysis
7.1.1.4   Key Strategies and Developments
7.1.1.4.1   Funding Activities
7.1.1.4.2   New Offerings
7.1.1.4.3   Mergers and Acquisitions
7.1.1.4.4   Partnerships, Alliances, and Business Expansions
7.1.1.4.5   Key Development Analysis
7.2   Company Share Analysis
7.3   Company Profiles
7.3.1   Becton, Dickinson and Company
7.3.1.1   Company Overview
7.3.1.2   Role of Becton, Dickinson and Company in the Global Cell and Gene Therapy Biomanufacturing Market
7.3.1.3   Major Product: Key Specifications
7.3.1.4   Customers and Competitions/Opportunities
7.3.1.4.1   Key Customers
7.3.1.4.2   Key Competitors
7.3.1.5   Analyst Perspective
7.3.2   Bio-Rad Laboratories, Inc.
7.3.2.1   Company Overview
7.3.2.2   Role of Bio-Rad Laboratories, Inc. in the Global Cell and Gene Therapy Biomanufacturing Market
7.3.2.3   Major Product: Key Specifications
7.3.2.4   Customers and Competitions/Opportunities
7.3.2.4.1   Key Customers
7.3.2.4.2   Key Competitors
7.3.2.5   Analyst Perspective
7.3.3   Bio-Techne Corporation
7.3.3.1   Company Overview
7.3.3.2   Role of Bio-Techne Corporation in the Global Cell and Gene Therapy Biomanufacturing Market
7.3.3.3   Major Product: Key Specifications
7.3.3.4   Customers and Competitions/Opportunities
7.3.3.4.1   Key Competitors
7.3.3.5   Analyst Perspective
7.3.4   Danaher Corporation
7.3.4.1   Company Overview
7.3.4.2   Role of Danaher Corporation in the Global Cell and Gene Therapy Biomanufacturing Market
7.3.4.3   Major Product: Key Specifications
7.3.4.4   Customers and Competitions/Opportunities
7.3.4.4.1   Key Competitors
7.3.4.5   Analyst Perspective
7.3.5   Endress+Hauser Group Services AG (Analytik Jena GmbH)
7.3.5.1   Company Overview
7.3.5.2   Role of Endress+Hauser Group Services AG (Analytik Jena GmbH) in the Global Cell and Gene Therapy Biomanufacturing Market
7.3.5.3   Major Product: Key Specifications
7.3.5.4   Customers and Competitions/Opportunities
7.3.5.4.1   Key Customers
7.3.5.4.2   Key Competitors
7.3.5.5   Analyst Perspective
7.3.6   General Electric Company (GE Healthcare)
7.3.6.1   Company Overview
7.3.6.2   Role of General Electric (GE HealthCare) in the Global Cell and Gene Therapy Biomanufacturing Market
7.3.6.3   Major Product: Key Specifications
7.3.6.4   Customers and Competitions/Opportunities
7.3.6.4.1   Key Competitors
7.3.6.5   Analyst Perspective
7.3.7   Getinge AB
7.3.7.1   Company Overview
7.3.7.2   Role of Getinge AB in the Global Cell and Gene Therapy Biomanufacturing Market
7.3.7.3   Major Product: Key Specifications
7.3.7.4   Customers and Competitions/Opportunities
7.3.7.4.1   Key Competitors
7.3.7.5   Analyst Perspective
7.3.8   Infors AG
7.3.8.1   Company Overview
7.3.8.2   Role of Infors AG in the Global Cell and Gene Therapy Biomanufacturing Market
7.3.8.3   Major Product: Key Specifications
7.3.8.4   Customers and Competitions/Opportunities
7.3.8.4.1   Key Competitors
7.3.8.5   Analyst Perspective
7.3.9   Lonza Group Ltd
7.3.9.1   Company Overview
7.3.9.2   Role of Lonza Group Ltd in the Global Cell and Gene Therapy Biomanufacturing Market
7.3.9.3   Major Product: Key Specifications
7.3.9.4   Customers and Competitions/Opportunities
7.3.9.4.1   Key Competitors
7.3.9.5   Analyst Perspective
7.3.10   Merck KGaA
7.3.10.1   Company Overview
7.3.10.2   Role of Merck KGaA in the Global Cell and Gene Therapy Biomanufacturing Market
7.3.10.3   Major Product: Key Specifications
7.3.10.4   Customers and Competitions/Opportunities
7.3.10.4.1   Key Competitors
7.3.10.5   Analyst Perspective
7.3.11   Miltenyi Biotec B.V. & Co. KG
7.3.11.1   Company Overview
7.3.11.2   Role of Miltenyi Biotec B.V. & Co. KG in the Global Cell and Gene Therapy Biomanufacturing Market
7.3.11.3   Major Product: Key Specifications
7.3.11.4   Customers and Competitions/Opportunities
7.3.11.4.1   Key Customers
7.3.11.4.2   Key Competitors
7.3.11.5   Analyst Perspective
7.3.12   PIERRE GUERIN
7.3.12.1   Company Overview
7.3.12.2   Role of PIERRE GUERIN in the Global Cell and Gene Therapy Biomanufacturing Market
7.3.12.3   Major Product: Key Specifications
7.3.12.4   Customers and Competitions/Opportunities
7.3.12.4.1   Key Competitors
7.3.12.5   Analyst Perspective
7.3.13   Sartorius AG (Sartorius Stedim Biotech S.A.)
7.3.13.1   Company Overview
7.3.13.2   Role of Sartorius AG (Sartorius Stedim Biotech S.A.) in the Global Cell and Gene Therapy Biomanufacturing Market
7.3.13.3   Major Product: Key Specifications
7.3.13.4   Customers and Competitions/Opportunities
7.3.13.4.1   Key Customers
7.3.13.4.2   Key Competitors
7.3.13.5   Analyst Perspective
7.3.14   Thermo Fisher Scientific Inc.
7.3.14.1   Company Overview
7.3.14.2   Role of Thermo Fisher Scientific Inc. in the Global Cell and Gene Therapy Biomanufacturing Market
7.3.14.3   Major Product: Key Specifications
7.3.14.4   Customers and Competitions/Opportunities
7.3.14.4.1   Key Competitors
7.3.14.5   Analyst Perspective
7.3.15   WuXi AppTec
7.3.15.1   Company Overview
7.3.15.2   Role of WuXi AppTec in the Global Cell and Gene Therapy Biomanufacturing Market
7.3.15.3   Major Product: Key Specifications
7.3.15.4   Customers and Competitions/Opportunities
7.3.15.4.1   Key Competitors
7.3.15.5   Analyst Perspective
7.4   Emerging Companies
7.4.1   elevatebio
7.4.2   Adva Biotechnology
7.4.3   Vineti

Table 1:   Key Questions Answered in the Report
Table 2:   Parameters for Realistic, Optimistic, and Pessimistic Growth Scenarios
Table 3:   Single-Use and Stainless-Steel Facilities, Comparative Analysis
Table 4:   Global Regulatory Scenario: Cell and Gene Therapy Biomanufacturing Market
Table 5:   Global Cell and Gene Therapy Biomanufacturing Market (by Product Type), Product Benchmarking
Table 6:   Comparative Analysis of Various Bioreactors Offered by Key Players
Table 7:   Global Cell and Gene Therapy Biomanufacturing Market, Awaited Technologies
Table 8:   Business Models, Key Features
Table 9:   Impact Analysis, Business Drivers
Table 10:   Impact Analysis, Business Restraints
Table 11:   Cell Culture Flask and Automated System, Comparative Analysis
Table 12:   North America Cell and Gene Therapy Biomanufacturing Market Dynamics, Impact Analysis
Table 13:   Europe Cell and Gene Therapy Biomanufacturing Market Dynamics, Impact Analysis
Table 14:   Asia-Pacific Cell and Gene Therapy Biomanufacturing Market Dynamics, Impact Analysis
Table 15:   Approved Cell and Gene Therapies, Japan
Table 16:   Ongoing Industry Sponsored Cell and Gene Therapy Clinical Trials
Table 17:   Latin America Cell and Gene Therapy Biomanufacturing Market Dynamics, Impact Analysis
Table 18:   Middle East and Africa Cell and Gene Therapy Biomanufacturing Market Dynamics, Impact Analysis
Table 19:   Global Cell and Gene Therapy Biomanufacturing Market, Key Development Analysis, January 2020-January 2023

Figure 1:   Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 2:   Cell and Gene Therapy Biomanufacturing Market: Drivers, Restraints, and Opportunities
Figure 3:   Global Cell and Gene Therapy Biomanufacturing Market, Impact Analysis
Figure 4:   Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion, 2021-2031
Figure 5:   Global Cell and Gene Therapy Biomanufacturing Market (by Region), $Billion, 2021 and 2031
Figure 6:   Global Cell and Gene Therapy Biomanufacturing Market, Share of Key Developments and Strategies (by Category), January 2020-January 2023
Figure 7:   Global Cell and Gene Therapy Biomanufacturing Market Segmentation
Figure 8:   Global Cell and Gene Therapy Biomanufacturing Market: Research Methodology
Figure 9:   Primary Research Methodology
Figure 10:   Bottom-Up Approach (Segment-Wise Analysis)
Figure 11:   Top-Down Approach (Segment-Wise Analysis)
Figure 12:   Global Cell and Gene Therapy Biomanufacturing Market, Potential Forecast Scenarios
Figure 13:   Global Cell and Gene Therapy Biomanufacturing Market Size and Growth Potential (Realistic Scenario), Billion, 2021-2031
Figure 14:   Global Cell and Gene Therapy Biomanufacturing Market Size and Growth Potential (Optimistic Scenario), $Billion, 2021-2031
Figure 15:   Global Cell and Gene Therapy Biomanufacturing Market Size and Growth Potential (Pessimistic Scenario), $Billion, 2021-2031
Figure 16:   Market Overview and Ecosystem
Figure 17:   Insights on Strategies Adopted by Major Players, January 2020-January 2023
Figure 18:   Global Cell and Gene Therapy Biomanufacturing Market, Key Trends, Market Shift, 2022-2031
Figure 19:   TcBuster vs. Viral Gene Engineering Technology, Comparative Analysis
Figure 20:   Global Cell and Gene Therapy Biomanufacturing Market, Patent Analysis (by Year), January 2020-December 2022
Figure 21:   Global Cell and Gene Therapy Biomanufacturing Market, Patent Analysis (by Country), January 2020-December 2022
Figure 22:   Anticipated Regulatory Milestones in 2023
Figure 23:   Anticipated Regulatory Approval, U.S. and EU, 2023
Figure 24:   Global Cell and Gene Therapy Biomanufacturing Market, Technology Adoption Matrix
Figure 25:   Global Cell and Gene Therapy Biomanufacturing Market, Key Success Factors
Figure 26:   FDA-Approved Cell and Gene Therapies, 2011-2022
Figure 27:   Global Incidence of Hematologic Malignancies (Leukemia, Multiple Myeloma and Immunoproliferative Diseases, and Non-Hodgkin’s Lymphoma), 2020 vs. 2040
Figure 28:   Number of Cell and Gene Therapy Developers (by Region)
Figure 29:   Global Investment in Cell and Gene Therapy Market, 2017-2022
Figure 30:   Volume and Value of Start-Up Financing, 2020-2021
Figure 31:   Ongoing Clinical Trials, Cell and Gene Therapies
Figure 32:   Impact of COVID-19 on CGT Developmental Activities
Figure 33:   Progress in Cell and Gene Therapy (CGT) Regulation during COVID-19
Figure 34:   Ways to Increase Supply Chain and Manufacturing
Figure 35:   Impact on Biopharmaceutical Industries
Figure 36:   Global Cell and Gene Therapy Biomanufacturing Market (by Product Type)
Figure 37:   Global Cell and Gene Therapy Biomanufacturing Market Incremental Opportunity (by Product Type), $Billion, 2021-2031
Figure 38:   Global Cell and Gene Therapy Biomanufacturing Market (Consumables), $Billion, 2021-2031
Figure 39:   Global Cell and Gene Therapy Biomanufacturing Market (Culture Supplements), $Billion, 2021-2031
Figure 40:   Global Cell and Gene Therapy Biomanufacturing Market (Media), $Billion, 2021-2031
Figure 41:   Global Cell and Gene Therapy Biomanufacturing Market (Serum), $Billion, 2021-2031
Figure 42:   Types of Macronutrients in Cell Culture Supplements
Figure 43:   Global Cell and Gene Therapy Biomanufacturing Market (Macronutrients), $Billion, 2021-2031
Figure 44:   Advantages of Using Single-Use Liquids
Figure 45:   Global Cell and Gene Therapy Biomanufacturing Market (Single-Use Liquids), $Billion, 2021-2031
Figure 46:   Global Cell and Gene Therapy Biomanufacturing Market (Cell Culture Reagents), $Billion, 2021-2031
Figure 47:   Global Cell and Gene Therapy Biomanufacturing Market (Cell Quantification Kits), $Billion, 2021-2031
Figure 48:   Global Cell and Gene Therapy Biomanufacturing Market (Equipment), $Billion, 2021-2031
Figure 49:   Global Cell and Gene Therapy Biomanufacturing Market (Bioreactors/Fermenters), $Billion, 2021-2031
Figure 50:   Global Cell and Gene Therapy Biomanufacturing Market (Continuous Bioreactors), $Billion, 2021-2031
Figure 51:   Global Cell and Gene Therapy Biomanufacturing Market (Single-Use Bioreactors), $Billion, 2021-2031
Figure 52:   Global Cell and Gene Therapy Biomanufacturing Market (Mixing Systems), $Billion, 2021-2031
Figure 53:   Global Cell and Gene Therapy Biomanufacturing Market (Cell Counters), $Billion, 2021-2031
Figure 54:   Global Cell and Gene Therapy Biomanufacturing Market (Cell Sorters), $Billion, 2021-2031
Figure 55:   Global Cell and Gene Therapy Biomanufacturing Market (Centrifuges), $Billion, 2021-2031
Figure 56:   Global Cell and Gene Therapy Biomanufacturing Market (Incubators), $Billion, 2021-2031
Figure 57:   Classes of Biosafety Cabinets
Figure 58:   Global Cell and Gene Therapy Biomanufacturing Market (Biosafety Cabinets), $Billion, 2021-2031
Figure 59:   Global Cell and Gene Therapy Biomanufacturing Market (Freezers), $Billion, 2021-2031
Figure 60:   Global Cell and Gene Therapy Biomanufacturing Market (PCR Systems), $Billion, 2021-2031
Figure 61:   Global Cell and Gene Therapy Biomanufacturing Market (Transfection Systems), $Billion, 2021-2031
Figure 62:   Global Cell and Gene Therapy Biomanufacturing Market (Storage Tanks), $Billion, 2021-2031
Figure 63:   Global Cell and Gene Therapy Biomanufacturing Market (Others), $Billion, 2021-2031
Figure 64:   Global Cell and Gene Therapy Biomanufacturing Market (Software Solutions), $Billion, 2021-2031
Figure 65:   Global Cell and Gene Therapy Biomanufacturing (by Application)
Figure 66:   Global Cell and Gene Therapy Biomanufacturing Market Incremental Opportunity (by Application), $Billion, 2021-2031
Figure 67:   Steps in Upstream Processing
Figure 68:   Global Cell and Gene Therapy Biomanufacturing Market (Upstream Processing), $Billion, 2021-2031
Figure 69:   Global Cell and Gene Therapy Biomanufacturing Market (Formulation and Hydration), $Billion, 2021-2031
Figure 70:   Steps in Cell Culture Processing
Figure 71:   Global Cell and Gene Therapy Biomanufacturing Market (Cell Culture Processing), $Billion, 2021-2031
Figure 72:   Global Cell and Gene Therapy Biomanufacturing Market (Harvesting), $Billion, 2021-2031
Figure 73:   Steps in Downstream Processing
Figure 74:   Global Cell and Gene Therapy Biomanufacturing Market (Downstream Processing), $Billion, 2021-2031
Figure 75:   Global Cell and Gene Therapy Biomanufacturing Market (Separation and Filtration), $Billion, 2021-2031
Figure 76:   Steps Involved in Fill and Finish Operations
Figure 77:   Global Cell and Gene Therapy Biomanufacturing Market (Fill and Finish Operations), $Billion, 2021-2031
Figure 78:   Global Cell and Gene Therapy Biomanufacturing Market (by Usage)
Figure 79:   Global Cell and Gene Therapy Biomanufacturing Market Incremental Opportunity (by Usage), $Billion, 2021-2031
Figure 80:   Important Steps in the Commercial Stage of Manufacturing
Figure 81:   Global Cell and Gene Therapy Biomanufacturing Market (Commercial Stage Manufacturing), $Billion, 2021-2031
Figure 82:   Global Cell and Gene Therapy Biomanufacturing Market (Research Stage Manufacturing), $Billion, 2021-2031
Figure 83:   Global Cell and Gene Therapy Biomanufacturing Market (by End User)
Figure 84:   Global Cell and Gene Therapy Biomanufacturing Market Incremental Opportunity (by End User), $Billion, 2021-2031
Figure 85:   Global Cell and Gene Therapy Biomanufacturing Market (Life Sciences Companies), $Billion, 2021-2031
Figure 86:   Global Cell and Gene Therapy Biomanufacturing Market (Equipment), $Billion, 2021-2031
Figure 87:   Global Cell and Gene Therapy Biomanufacturing Market (Consumables), $Billion, 2021-2031
Figure 88:   Global Cell and Gene Therapy Biomanufacturing Market (Software Solutions), $Billion, 2021-2031
Figure 89:   Global Cell and Gene Therapy Biomanufacturing Market (Contract Research Organizations (CROs)), $Billion, 2021-2031
Figure 90:   Global Cell and Gene Therapy Biomanufacturing Market (Equipment), $Billion, 2021-2031
Figure 91:   Global Cell and Gene Therapy Biomanufacturing Market (Consumables), $Billion, 2021-2031
Figure 92:   Global Cell and Gene Therapy Biomanufacturing Market (Software Solutions), $Billion, 2021-2031
Figure 93:   Global Cell and Gene Therapy Biomanufacturing Market (Contract Manufacturing Organizations (CMOs)), $Billion, 2021-2031
Figure 94:   Global Cell and Gene Therapy Biomanufacturing Market (Equipment), $Billion, 2021-2031
Figure 95:   Global Cell and Gene Therapy Biomanufacturing Market (Consumables), $Billion, 2021-2031
Figure 96:   Global Cell and Gene Therapy Biomanufacturing Market (Software Solutions), $Billion, 2021-2031
Figure 97:   Global Cell and Gene Therapy Biomanufacturing Market (Cell Banks), $Billion, 2021-2031
Figure 98:   Global Cell and Gene Therapy Biomanufacturing Market (Equipment), $Billion, 2021-2031
Figure 99:   Global Cell and Gene Therapy Biomanufacturing Market (Consumables), $Billion, 2021-2031
Figure 100:   Global Cell and Gene Therapy Biomanufacturing Market (Software Solutions), $Billion, 2021-2031
Figure 101:   Global Cell and Gene Therapy Biomanufacturing Market Share (by Region)
Figure 102:   North America Cell and Gene Therapy Biomanufacturing Market Incremental Revenue Opportunity (by Country), $Billion, 2021-2031
Figure 103:   Ongoing Clinical Trials, North America (by Country)
Figure 104:   Leukemia, Incidence, 2020 vs. 2040
Figure 105:   Multiple Myeloma and Immunoproliferative Diseases, Incidence, 2020 vs. 2040
Figure 106:   North America Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 107:   North America Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion, 2021-2031
Figure 108:   North America Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion, 2021-2031
Figure 109:   Rate of Hematologic Malignancies (by Age and Cancer Type), U.S.
Figure 110:   U.S. Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 111:   U.S. Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 112:   U.S. Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 113:   Incidence of Multiple Myeloma and Immunoproliferative Diseases and Non-Hodgkin’s Lymphoma, Canada, 2020 vs. 2040
Figure 114:   Canada Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 115:   Canada Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 116:   Canada Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 117:   Europe Cell and Gene Therapy Biomanufacturing Market Incremental Revenue Opportunity (by Country), $Billion, 2021-2031
Figure 118:   Ongoing Clinical Trials, Europe (by Country)
Figure 119:   Leukemia, Incidence, 2020 vs. 2040
Figure 120:   Multiple Myeloma, Incidence, 2020 vs. 2040
Figure 121:   Non-Hodgkin’s Lymphoma, Incidence, 2020 vs. 2040
Figure 122:   Europe Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 123:   Europe Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion, 2021-2031
Figure 124:   Europe Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion, 2021-2031
Figure 125:   Incidence of Leukemia, Multiple Myeloma, and Non-Hodgkin’s Lymphoma, Germany, 2020 vs. 2040
Figure 126:   Germany Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 127:   Germany Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 128:   Germany Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 129:   Italy Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 130:   Italy Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 131:   Italy Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 132:   Incidence of Leukemia, Multiple Myeloma, and Non-Hodgkin’s Lymphoma, U.K., 2020 vs. 2040
Figure 133:   U.K. Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 134:   U.K. Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 135:   U.K. Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 136:   Incidence of Leukemia, Multiple Myeloma, and Non-Hodgkin’s Lymphoma, Spain, 2020 vs. 2040
Figure 137:   Spain Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 138:   Spain Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 139:   Spain Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 140:   Incidence of Leukemia, Multiple Myeloma, and Non-Hodgkin’s Lymphoma, France, 2020 vs. 2040
Figure 141:   France Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 142:   France Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 143:   France Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 144:   Rest-of-Europe Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 145:   Rest-of-Europe Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 146:   Rest-of-Europe Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 147:   Asia-Pacific Cell and Gene Therapy Biomanufacturing Market Incremental Revenue Opportunity (by Country), $Billion, 2021-2031
Figure 148:   Ongoing Clinical Trials, Asia-Pacific (by Country)
Figure 149:   Incidence of Hematologic Malignancies, Asia, 2020 vs. 2040
Figure 150:   Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 151:   Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion, 2021-2031
Figure 152:   Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion, 2021-2031
Figure 153:   China Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 154:   China Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 155:   China Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 156:   Japan Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 157:   Japan Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 158:   Japan Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 159:   Incidence of Leukemia, Multiple Myeloma and Immunoproliferative Diseases, and Non-Hodgkin’s Lymphoma, India, 2020 vs. 2040
Figure 160:   India Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 161:   India Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 162:   India Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 163:   Incidence of Leukemia, Multiple Myeloma and Immunoproliferative Diseases, and Non-Hodgkin’s Lymphoma, South Korea, 2020 vs. 2040
Figure 164:   South Korea Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 165:   South Korea Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 166:   South Korea Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 167:   Australia/New Zealand Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 168:   New Zealand Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 169:   Australia/New Zealand Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 170:   Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 171:   Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 172:   Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 173:   Latin America Cell and Gene Therapy Biomanufacturing Market Incremental Revenue Opportunity (by Country), $Billion, 2021-2031
Figure 174:   Ongoing Clinical Trials, Latin America (by Country)
Figure 175:   Leukemia, Multiple Myeloma and Immunoproliferative Diseases, and Non-Hodgkin’s Lymphoma, Incidence, Latin America and Caribbean, 2020 vs. 2040
Figure 176:   Latin America Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 177:   Latin America Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion, 2021-2031
Figure 178:   Latin America Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion, 2021-2031
Figure 179:   Incidence of Leukemia, Multiple Myeloma and Immunoproliferative Diseases, and Non-Hodgkin’s Lymphoma, Argentina, 2020 vs. 2040
Figure 180:   Argentina Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 181:   Argentina Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 182:   Argentina Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 183:   Incidence of Myeloma and Immunoproliferative Diseases and Non-Hodgkin’s Lymphoma, Brazil, 2020 vs. 2040
Figure 184:   Brazil Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 185:   Brazil Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 186:   Brazil Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 187:   Incidence of Leukemia and Non-Hodgkin’s Lymphoma, Mexico, 2020 vs. 2040
Figure 188:   Mexico Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 189:   Mexico Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 190:   Mexico Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 191:   Rest-of-Latin America Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 192:   Rest-of-Latin America Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 193:   Rest-of-Latin America Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 194:   Middle East and Africa Cell and Gene Therapy Biomanufacturing Market Incremental Revenue Opportunity (by Country), $Billion, 2021-2031
Figure 195:   Incidence of Hematologic Cancers (Leukemia, Multiple Myeloma and Immunoproliferative Diseases, and Non-Hodgkin’s Lymphoma), Africa, 2020 vs. 2040
Figure 196:   Ongoing Clinical Trials, Middle East and Africa (by Country)
Figure 197:   Middle East and Africa Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 198:   Middle East and Africa Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion, 2021-2031
Figure 199:   Middle East and Africa Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion, 2021-2031
Figure 200:   Kingdom of Saudi Arabia Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 201:   Kingdom of Saudi Arabia Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 202:   Kingdom of Saudi Arabia Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 203:   Incidence of Multiple Myeloma and Immunoproliferative Diseases and Non-Hodgkin’s Lymphoma, U.A.E., 2020 vs. 2040
Figure 204:   U.A.E. Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 205:   U.A.E. Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 206:   U.A.E. Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 207:   Incidence of Leukemia and Non-Hodgkin’s Lymphoma, Israel, 2020 vs. 2040
Figure 208:   Israel Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 209:   Israel Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 210:   Israel Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 211:   Rest-of-Middle East and Africa Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 212:   Rest-of-Middle East and Africa Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 213:   Rest-of-Middle East and Africa Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 214:   Growth Share Analysis for Global Cell and Gene Therapy Biomanufacturing Market (by Product Type), 2021-2031
Figure 215:   Growth Share Analysis for Global Cell and Gene Therapy Biomanufacturing Market (by Application), 2021-2031
Figure 216:   Competitive Index, Unmet Needs, Solutions, and Impacts
Figure 217:   Company Position Analysis
Figure 218:   Global Cell and Gene Therapy Biomanufacturing Market, Total Number of Key Developments, January 2020-January 2023
Figure 219:   Funding Activities, January 2020-January 2023
Figure 220:   New Offerings, January 2020-September 2023
Figure 221:   Mergers and Acquisitions, January 2020-January 2023
Figure 222:   Partnerships, Alliances, and Business Expansion Activities, January 2020-January 2023
Figure 223:   Global Cell and Gene Therapy Biomanufacturing Market, Company Share Analysis, % Share, 2021
Figure 224:   Becton, Dickinson and Company: Product Portfolio
Figure 225:   Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 226:   Bio-Techne Corporation: Product Portfolio
Figure 227:   Danaher Corporation: Product Portfolio
Figure 228:   Endress+Hauser Group Services AG (Analytik Jena GmbH): Product Portfolio
Figure 229:   General Electric Company (GE Healthcare): Product Portfolio
Figure 230:   Getinge AB: Product Portfolio
Figure 231:   Infors AG: Product Portfolio
Figure 232:   Lonza Group Ltd: Product Portfolio
Figure 233:   Merck KGaA: Product Portfolio
Figure 234:   Miltenyi Biotec B.V. & Co. KG: Product Portfolio
Figure 235:   PIERRE GUERIN: Product Portfolio
Figure 236:   Sartorius AG (Sartorius Stedim Biotech S.A.): Product Portfolio
Figure 237:   Thermo Fisher Scientific Inc.: Product Portfolio
Figure 238:   WuXi AppTec: Product Portfolio

Market Report Coverage

Cell and Gene Therapy Biomanufacturing Market
Base Year	2021	Market Size in 2022	$12.31 Billion
Forecast Period	2022-2031	Value Projection and Estimation by 2031	$29.76 Billion
CAGR During Forecast Period	10.31%	Number of Tables	19
Number of Pages	308	Number of Figures	238

Key Market Players and Competition Synopsis

The success of cell- and gene-based therapies has sparked efforts to promote treatments. A stronger focus on the biomanufacturing demand has become essential as the need to cater to the clinical and commercial production of cells, together with the growing amount of substantial clinical data resulting from these therapies, arises. The increased demand for treatments is fuelling the expansion of cell and gene therapy biomanufacturers and providing them with numerous opportunities to spread out across different regions and improve their market presence.

Key Companies Profiled

•   Becton, Dickinson and Company
•   Bio-Rad Laboratories, Inc.
•   Bio-Techne Corporation
•   Danaher Corporation
•   Endress+Hauser Group Services AG (Analytik Jena GmbH)
•   General Electric Company (GE Healthcare)
•   Getinge AB
•   Infors AG
•   Lonza Group Ltd
•   Merck KGaA
•   Miltenyi Biotec B.V. & Co. KG
•   PIERRE GUERIN
•   Sartorius AG (Sartorius Stedim Biotech S.A.)
•   Thermo Fisher Scientific Inc.
•   WuXi AppTec

How can this report add value to an organization?

Workflow/Innovation Strategy: The cell and gene therapy biomanufacturing market (by product type) has been segmented into consumables, equipment, and software solutions. Moreover, the study provides the reader with a detailed understanding of the different applications of cell and gene therapy biomanufacturing in upstream processing, harvesting, and downstream processing.

Growth/Marketing Strategy: Cell and gene therapy biomanufacturing is being used for upstream processing, harvesting, downstream processing, and other applications. Various companies are providing consumables and equipment aid in the manufacturing of various cell and gene therapies, which is also the key strategy for market players to excel in the current cell and gene therapy biomanufacturing market.

Competitive Strategy: Key players in the global cell and gene therapy biomanufacturing market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the global cell and gene therapy biomanufacturing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Cell and Gene Therapy Biomanufacturing Industry and Technology Overview

The global cell and gene therapy biomanufacturing market was valued at $12.31 billion in 2022 and is anticipated to reach $29.76 billion by 2031, witnessing a CAGR of 10.31% during the forecast period 2022-2031. The growth in the global cell and gene therapy biomanufacturing market is expected to be driven by the increased number of approved therapies and growing infrastructure requirements. In addition, expansion in target indications for cell and gene therapies creates a demand for large-scale biomanufacturing.

Cell and Gene Therapy Biomanufacturing Market Lifecycle Stage

The global cell and gene therapy biomanufacturing market is in progressing phase. The cell and gene therapy market is developing rapidly due to its potential to target chronic and rare/orphan diseases that earlier had limited treatment options. Cell and gene therapies available in the market or in the pipeline are the result of years of pioneering research. Currently, there are more than 25 cell and gene therapies approved by the FDA in the last 10 years. These factors are expected to drive the demand for consumables, equipment, and software solutions required for manufacturing cell and gene therapy, thereby augmenting the growth of the cell and gene therapy biomanufacturing market.

Moreover, manufacturers began to produce application-specific cell and gene therapy equipment in recent years.

Figure 1: Global Cell and Gene Therapy Biomanufacturing Market Snapshot

Source: BIS Research Analysis

Impact

The field of medicine is transformed with the commercialization of cell and gene therapies. With the advent of time and introduction of new technologies, cell and gene therapy areas are flourishing. There is constant ongoing research for the development of novel cell and gene therapies. According to the American Society of Gene + Cell Therapy (ASGCT), as of February 2023, there are more than 2,000 clinical trials in the pipeline. The robust clinical pipeline for novel cell and gene entities is expected to create a lucrative opportunity for manufacturers and boost the growth of the cell and gene therapy biomanufacturing market.

Impact of COVID-19

In December 2019, Wuhan, a city in the Hubei region of China, was the site of the first detection of the COVID-19 outbreak. Following the classification of COVID-19 as novel pneumonia due to a cluster of unexplained pneumonia cases, efforts to pinpoint the culprit causing the outbreak and outline its genomic sequence got underway right once. The virus has already spread to every country on the globe, and researchers, governments, and business leaders are working to find answers to the crisis at a scale and speed that has never been seen. Testing for SARS-CoV-2 in the populace is one of the main steps that has been put into place globally, among many other measures used to stop the spread of the disease. The most crucial benefit of testing is that it offers evidence of illness, enabling individuals and those they have come into contact with to take the required precautions, including quarantining, to minimize community exposure.

The COVID-19 pandemic has substantially interrupted social, economic, and political activity around the world due to its unparalleled size and intensity. As a result, the cell and gene therapy (CGT) sector, which has historically struggled with tremendous complexity in the supply of materials, production, and logistical operations, has been disrupted by COVID-19.

The research, production, clinical development, and market introduction of CGTs for diseases unrelated to COVID-19 have all been significantly disrupted as a result of the COVID-19 pandemic. A lack of manufacturing material supplies, challenges with clinical studies, and delay in the creation of regulatory dossiers are all significant reasons. This has emphasized the significance of tackling the difficulties in CGTs' supply chain and production to increase resilience during the crisis.

To prevent CGTs' market access from being significantly disrupted, manufacturing resilience, digitalization, telemedicine, value-based pricing, and creative payment systems may be progressively tapped.

Market Segmentation:

Segmentation 1: by Product Type
•   Consumables
•   Equipment
•   Software Solutions

Based on product, the consumables segment in the global cell and gene therapy biomanufacturing market dominated in FY2021. The equipment has a shelf life of five to seven years and software solutions also require a one-time investment with yearly maintenance costs. However, consumables are required more frequently and in large quantities for the production of cell and gene therapies.

Segmentation 2: by Usage
• Commercial Stage Manufacturing
• Research Stage Manufacturing

Based on usage, the global cell and gene therapy biomanufacturing market was dominated by the research stage manufacturing segment in FY2021.

Segmentation 3: by Application
•   Upstream Processing
•   Harvesting
•   Downstream Processing

Based on application, the downstream processing segment accounted for the largest share of the global cell and gene therapy biomanufacturing in FY2021.

Segmentation 4: by End User
•   Life Science Companies
•   Contract Research Organizations (CROs)
•   Contract Manufacturing Organizations (CMOs)
•   Cell Banks

Based on end user, the global cell and gene therapy biomanufacturing market is dominated by the life sciences companies segment in FY2021.

Segmentation 5: by Region
•   North America
•   Europe
•   Asia-Pacific
•   Latin America
•   Middle East and Africa

In 2021, the North America cell and gene therapy biomanufacturing market dominated the global market with a 44.70% market share, and it is expected to hold its dominance throughout the forecast period 2022-2031. However, the Asia-Pacific (APAC) region, constituting several emerging economies, is expected to register the highest CAGR of 17.88% during the forecast period 2022-2031.

Recent Developments in the Global Cell and Gene Therapy Biomanufacturing Market

•   In January 2023, Sartorius AG collaborated with Roosterbio Inc. to advance its downstream purification processes for the development of exosomes.
•   In February 2022, Sartorius AG completed the acquisition of Novasep's chromatography division to complement its own product portfolio.
•   In August 2022, Merck KGaA launched VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform to speed up the development of cell and gene therapies.
•   In June 2022, Lonza Group AG and Adva Biotechnology Ltd. entered into a license agreement that provides the latter access to the former's core intellectual property enabling the expansion of automated bioreactors worldwide.
•   In June 2022, Becton, Dickinson and Company launched FACSDiscover S8 Cell Sorter featuring CellView Image Technology.
•   In January 2023, Bio-Techne Corporation launched RNAscope plus assay to advance its gene therapy development.
•   In September 2021, Thermo Fisher Scientific Inc. launched the integrated Gibco AAV-MAX Helper Free AAV Production System for AAV vector production.

Demand - Drivers and Limitations

The following are the demand drivers for the global cell and gene therapy biomanufacturing market:

•   Increasing Number of Approved Therapies and Growing Infrastructure Requirements Creating an Upsurge Demand for Cell and Gene Therapy Biomanufacturing Products
•   Expansion in Target Indications for Cell and Gene Therapies Creating a Demand for Large-Scale Biomanufacturing
•   Entry of New Market Participants in Cell and Gene Therapies Driving the Demand for Biomanufacturing Facilities and Equipment
•   Increasing Investments and Fundings in Cell and Gene Therapy Fuelling the Growth of Cell and Gene Therapy Biomanufacturing

The market is expected to face some limitations due to the following challenges:

• High Set-Up Cost of Biomanufacturing Facilities

Analyst View

According to Akash Mhaskar, Principal Analyst, BIS Research, “The global cell and gene therapy biomanufacturing market is strongly driven by the rising incidence of target diseases such as orphan diseases, cancers, metabolic disorders, and autoimmune disorders, among others, as well as the increasing approval of cell and gene therapies. The global cell and gene therapy biomanufacturing market has witnessed a steady growth in the number of new entrants and investments in cell and gene therapy, thereby driving a surge in demand for the consumables, equipment, and software solutions required in the manufacturing of these therapies. This trend is also expected to continue over the forecast period. Therefore, the impact of the aforementioned factors is expected to drive the global cell and gene therapy biomanufacturing market in the near future.”

Cell and Gene Therapy Biomanufacturing Market - A Global and Regional Analysis

Focus on Product Type, Application, Usage, End User, and Region - Analysis and Forecast, 2022-2031

Get Free Sample

Schedule a Call

Some Faq's

Frequently Asked Questions

The process of producing cell- and gene-based therapies by using cells and genes for the treatment of various diseases is known as biomanufacturing. Oftentimes, these treatments use living cells that have been genetically modified to create therapeutic proteins or to replace sick or damaged cells in the patient's body. The advancement in cell and gene therapy biomanufacturing has propelled biological and biomedical research to a great extent. The study defines cell and gene therapy biomanufacturing market products as consumables, equipment, and software solutions used for similar purposes.

New technologies and methods are rapidly emerging to enhance the manufacture and delivery of these medicines, which is driving the market for cell and gene therapy biomanufacturing. Here are some prevalent patterns in the industry:

• Increased emphasis on automation: As the market for cell and gene therapies expands, more effective and scalable production techniques are becoming increasingly important. Artificial intelligence and robotics are two automation technologies that are rapidly being used to streamline the biomanufacturing process, lower costs, and enhance quality control.

• Production capacity expansion for cell and gene therapies: To address the rising demand for these treatments, many businesses in the industry are expanding their manufacturing capabilities. To enhance production quantities, this includes building new production plants and expanding current ones.

• Adoption of closed and variable manufacturing systems: The market for cell and gene therapy biomanufacturing is seeing an increase in the adoption of closed and variable manufacturing systems. These systems are made to reduce the possibility of contamination and improve the effectiveness of the production process.
These are only a few illustrations of the major developments in the industry for cell and gene therapy manufacturing. Emerging innovations and technologies are anticipated to emerge as the area develops further, helping to influence the industry's future.

The global cell and gene therapy biomanufacturing market is currently witnessing several developments, primarily aimed toward bringing new products and services. Major manufacturers of cell and gene therapy biomanufacturing products, along with the service providers, are actively undertaking significant business strategies to translate success in research and development into the commercial clinical setting. Companies such as Sartorius AG, Merck KGaA, Lonza Group AG, Thermo Fisher Scientific Inc., and Bio-Rad Laboratories, Inc. have majorly adopted partnerships, collaborations, and joint venture strategies.

A new entrant can focus on various cell and gene therapy biomanufacturing product offerings by established players. The market is fragmented with established market leaders such as Sartorius AG, Merck KGaA, Lonza Group AG, Thermo Fisher Scientific Inc., and Bio-Rad Laboratories, Inc., who have had their presence in the market for the past many years. The new entrants can focus on their strategy of product launches and global expansions for cell and gene therapy biomanufacturing.

•   The major USP of the report is the inclusion of software solutions along with the consumables and equipment required for the manufacturing of cell and gene therapy.
•   The report provides numerical projections for the product type as well as end user in each geography.
•   Additionally, the report also provides insights on COVID-19 and Russo-Ukrainian War on the global cell and gene therapy biomanufacturing market.
•   Apart from this, the report focuses on key trends such as biomanufacturing 4.0 and assessment of the trends as well.
•   The report also comprises key regulations, competitive landscape, key drivers and restraints, patent analysis, business model analysis, and company profiles with a detailed analysis of the strategies undertaken by the major company to strengthen its market presence.

•   Companies that manufacture and commercialize consumables and equipment required in the biomanufacturing of cell and gene therapy
•   Any new entrant that wants to know where the opportunities lie in the cell and gene therapy biomanufacturing market
•   Any established player that wants to expand its product portfolio or business in new geographies

Global Cell and Gene Therapy Drug Delivery Devices Market: Focus on Product Type, Commercialized Dru

The global cell and gene therapy drug delivery devices market was valued at $55.75 thousand in...

View Report

Published Year: 2021

Global Cell and Gene Therapy Manufacturing QC Market: Focus on Products and Services, Process, Analy

The global market for cell and gene therapy manufacturing QC is predicted to grow at a CAGR of...

View Report

Published Year: 2021

Global Cell and Gene Therapy Market: Focus on Product Type, Therapeutic Class, Pipeline, Regional an

The global cell and gene therapy market was valued at $2,599.7 million in 2020, and it is...

View Report

A quick peek into the report

Table of Contents

Market Report Coverage

How can this report add value to an organization?

Cell and Gene Therapy Biomanufacturing Industry and Technology Overview

$5500

Cell and Gene Therapy Biomanufacturing Market - A Global and Regional Analysis

Frequently Asked Questions

You may also like

Global Cell and Gene Therapy Drug Delivery Devices Market: Focus on Product Type, Commercialized Dru

Global Cell and Gene Therapy Manufacturing QC Market: Focus on Products and Services, Process, Analy

Global Cell and Gene Therapy Market: Focus on Product Type, Therapeutic Class, Pipeline, Regional an

Cell and Gene Therapy Biomanufacturing Market - A Global and Regional Analysis

A quick peek into the report

Table of Contents

1 Markets

2 Global Cell and Gene Therapy Biomanufacturing Market (by Product Type)

3 Global Cell and Gene Therapy Biomanufacturing Market (by Application)

4 Global Cell and Gene Therapy Biomanufacturing Market (by Usage)

5 Global Cell and Gene Therapy Biomanufacturing Market (by End User)

6 Global Cell and Gene Therapy Biomanufacturing Market (by Region)

7 Markets - Competitive Benchmarking and Company Profiles

List of Tables

List of Figures

Market Report Coverage

How can this report add value to an organization?

Cell and Gene Therapy Biomanufacturing Industry and Technology Overview

$5500

Cell and Gene Therapy Biomanufacturing Market - A Global and Regional Analysis

Frequently Asked Questions

Q: What is cell and gene therapy biomanufacturing?

Q: What are the key trends in the cell and gene therapy biomanufacturing market?

Q: What kinds of new strategies are being adopted by the existing market players to strengthen their market positions in the industry?

Q: For a new company looking to enter the global cell and gene therapy biomanufacturing market, which areas could it focus on to stay ahead of the competition?

Q: What is the USP of this report?

Q: Who should buy this report?

You may also like

Global Cell and Gene Therapy Drug Delivery Devices Market: Focus on Product Type, Commercialized Dru

Global Cell and Gene Therapy Manufacturing QC Market: Focus on Products and Services, Process, Analy

Global Cell and Gene Therapy Market: Focus on Product Type, Therapeutic Class, Pipeline, Regional an